imiquimod
Commercial- Indications
- Actinic keratosis, External genital warts, Superficial basal cell carcinoma
Company intelligence / Profile preview
Graceway Pharmaceuticals was a specialty pharmaceutical company focused on acquiring and developing branded prescription products primarily in dermatology but also respiratory and women's health. Its lead commercial assets included topical immune response modifiers like Aldara® and Zyclara® for actinic keratoses/warts/carcinoma. The company filed for bankruptcy in September 2011 after which its product portfolio—including several mid-to-late-stage pipeline assets—was acquired by Medicis Pharmaceutical Corporation. At the time of sale, annual revenues exceeded $125 million from approved products.
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Graceway Pharmaceuticals.